 Artist: Lillian Axe: mp3 download Genre(s): Other Metal: Heavy Rock: Hard-Rock Lillian Axe's discography:  Live 2002 (CD 2) Year: 2002 Tracks: 11  Live 2002 (CD 1) Year: 2002 Tracks: 10  Fields Of Yesterday Year: 1999 Tracks: 12  Psychoschizophrenia Year: 1993 Tracks: 12  Poetic Justice Year: 1992 Tracks: 13  Love And War Year: 1989 Tracks: 10  Love + War Year: 1989 Tracks: 10  Lillian Axe Year: 1988 Tracks: 10 Classical-guitar training gives Stevie Blaze and Lillian Axe a comparably ordered expressive style of hard-rock. They've produced four albums, including 1993's Psychoschizophrenia on IRS Records. The grade insignia besides involves vocalist Ron Taylor, keyboardist Jon Ster, bassist Darrin Delatte, and drummer Tommy Scott. William Claude Dukenfield of Yesterday was issued in 1999. |
Tuesday, 9 September 2008
Mp3 music: Lillian Axe
Sunday, 31 August 2008
Peakdale Molecular Launches AssayReady4U(TM) In Collaboration With ChemPrintCo LLC
�AssayReady4U(TM) is an online based shopfront which allows drug
discovery researchers the ability to search, invention and blue-ribbon compounds from
a live physical solicitation of screening compounds. Then, using additional
options, build their final assay by selecting the exact measure and
assiduity required to perform their own unique experiments.
The final customer-selected compounds are cleanly and
accurately dispensed into SBS measure well plates of the customer's choosing
using ChemPrintCo's sophisticated and proprietary hydro-acoustic
technologies. Each AssayReady4U plate is sealed in an argon environment and
then vacuum-sealed in a moisture barrier bag and placed inside a
temperature-controlled pack for shipment. All orders are shipped from stock
within 24 hours of completion using a commercial carrier. Upon receipt, the
customer adds an set aside amount of solvent to reach the desired test
concentration.
Peakdale's collection is fundamentally rich in novel,
GPCR-targeted compounds. All compounds in the collection are selected for
their pertinency to GPCR research. Well-recognized ligand features are
combined with proprietorship scaffolds and monomers to produce a set of
screening compounds for GPCR hit discovery.
Glenn Killingworth, Director of Business Development at
Peakdale said: "I am frantic that we have reinforced this collaborationism in order
to reach out the smaller drug-research groups who don't want to build assets to
computer storage, handle and plate compounds, but but want to receive ready-to-screen
assays from a high quality collection, in on the nose the format that they need
to perform their drug discovery work."
Peakdale's Director of Technology Paul Doyle aforementioned: "This
represents an exciting new technology that allows a a great deal broader base of
researchers to access the world of various compounds in a cost effective
mode."
Adding to this, ChemPrintCo's Vice President of Sales Ron Jones said:
"The AssayReady4U(TM) products will be offered via an innovational web-based
one-stop shopping shopfront. The researchers will effortlessly select
compounds, assay test concentration, plate format, plate manufacturer and
controls with a few clicks of a mouse thus optimizing their valuable time for
research."
�About Peakdale Molecular
Peakdale Molecular was founded in 1992. Today the company's
customers include the majority of the major spherical pharmaceutical businesses
and a rapidly growing base of biotechnology companies worldwide. Peakdale's
teams of chemists combine experience in pharmaceutical R&D, medicinal
chemistry, parallel synthesis, process developing and fine chemicals to
deliver singular chemistry solutions to a range of drug discovery challenges.
Peakdale has growing capabilities in computational alchemy, analytical
alchemy and ADME screening.
The application of less unremarkably used chemistry, including
high gear temperature/pressure reactions, proprietary heterocyclic compound chemistry and
nucleoside synthesis, enables Peakdale's chemists to generate unique
compounds for drug discovery. Peakdale operates in several distinct markets
providing novel screening compounds, targeted covering libraries, catalogue
intermediates, custom synthesis and contract research. Further information
about the company can be obtained at hTTP://www.peakdale.com
About ChemPrintCo LLC
ChemPrintCo is a privately held ship's company located in the pump
of Silicon Valley and the Bay Area's deep biotech and pharmaceutical
community. The management team has been together for all over 15 days developing
unique and cost-efficient products and systems for the biotech and
high tech industries. Their mission is to address the needs of the
individual scientific researcher with ready-to-use assays in a single-use
easily plate format. We carry out this by giving each researcher the ability
to select compounds from starring suppliers in the exact amount and
concentration required to perform their possess unique experiments.
Peakdale Molecular
More info
discovery researchers the ability to search, invention and blue-ribbon compounds from
a live physical solicitation of screening compounds. Then, using additional
options, build their final assay by selecting the exact measure and
assiduity required to perform their own unique experiments.
The final customer-selected compounds are cleanly and
accurately dispensed into SBS measure well plates of the customer's choosing
using ChemPrintCo's sophisticated and proprietary hydro-acoustic
technologies. Each AssayReady4U plate is sealed in an argon environment and
then vacuum-sealed in a moisture barrier bag and placed inside a
temperature-controlled pack for shipment. All orders are shipped from stock
within 24 hours of completion using a commercial carrier. Upon receipt, the
customer adds an set aside amount of solvent to reach the desired test
concentration.
Peakdale's collection is fundamentally rich in novel,
GPCR-targeted compounds. All compounds in the collection are selected for
their pertinency to GPCR research. Well-recognized ligand features are
combined with proprietorship scaffolds and monomers to produce a set of
screening compounds for GPCR hit discovery.
Glenn Killingworth, Director of Business Development at
Peakdale said: "I am frantic that we have reinforced this collaborationism in order
to reach out the smaller drug-research groups who don't want to build assets to
computer storage, handle and plate compounds, but but want to receive ready-to-screen
assays from a high quality collection, in on the nose the format that they need
to perform their drug discovery work."
Peakdale's Director of Technology Paul Doyle aforementioned: "This
represents an exciting new technology that allows a a great deal broader base of
researchers to access the world of various compounds in a cost effective
mode."
Adding to this, ChemPrintCo's Vice President of Sales Ron Jones said:
"The AssayReady4U(TM) products will be offered via an innovational web-based
one-stop shopping shopfront. The researchers will effortlessly select
compounds, assay test concentration, plate format, plate manufacturer and
controls with a few clicks of a mouse thus optimizing their valuable time for
research."
�About Peakdale Molecular
Peakdale Molecular was founded in 1992. Today the company's
customers include the majority of the major spherical pharmaceutical businesses
and a rapidly growing base of biotechnology companies worldwide. Peakdale's
teams of chemists combine experience in pharmaceutical R&D, medicinal
chemistry, parallel synthesis, process developing and fine chemicals to
deliver singular chemistry solutions to a range of drug discovery challenges.
Peakdale has growing capabilities in computational alchemy, analytical
alchemy and ADME screening.
The application of less unremarkably used chemistry, including
high gear temperature/pressure reactions, proprietary heterocyclic compound chemistry and
nucleoside synthesis, enables Peakdale's chemists to generate unique
compounds for drug discovery. Peakdale operates in several distinct markets
providing novel screening compounds, targeted covering libraries, catalogue
intermediates, custom synthesis and contract research. Further information
about the company can be obtained at hTTP://www.peakdale.com
About ChemPrintCo LLC
ChemPrintCo is a privately held ship's company located in the pump
of Silicon Valley and the Bay Area's deep biotech and pharmaceutical
community. The management team has been together for all over 15 days developing
unique and cost-efficient products and systems for the biotech and
high tech industries. Their mission is to address the needs of the
individual scientific researcher with ready-to-use assays in a single-use
easily plate format. We carry out this by giving each researcher the ability
to select compounds from starring suppliers in the exact amount and
concentration required to perform their possess unique experiments.
Peakdale Molecular
More info
Thursday, 21 August 2008
Comparing Intermittent To Continuous Androgen Deprivation For Advanced Prostate Cancer
�UroToday.com - Dr. Arto Salonen and Finnish colleagues compared intermittent androgen privation (IAD) to continuous androgenic hormone deprivation (CAD) in 856 patients with locally advanced or metastatic prostate cancer (CaP) treated at 27 clinics in Finland. This report represents an meantime analysis of their data.
The patients were accrued between 1997 and 2003 and had a life expectancy of at least 12 months. A 24 week flow in of continuous LHRH agonist therapy preceded randomisation for those who had a PSA decrease to
Mean patient role age was 72 days and hateful PSA at entry was 383ng/ml. Patients had point T3 tumors (61%) and stage T4 tumors (29%). A come of 564 men completed the row period and 279 were randomized to IAD and 285 to CAD. PSA, alkaline phosphatase, proportion of T4 tumors, poorly differentiated tumors, metastatic disease, and skeletal hot spots among patients with M1 disease were significantly higher in the IAD group. Baseline testosterone was not important in the analysis.
A significant proportion of patients with the most fast-growing and advance CaP did not reply to androgenic hormone deprivation therapy. The investigators concluded that IAD appears feasible for patients with locally advanced, hormone sore CaP. A low limit of testosterone at baseline did non select for IAD or CAD. Patients with advanced CaP, with a high PSA, alkaline phosphatase and metastatic disease, with more than 5 skeletal hot spots, did not read adequate biochemical response to ADT. Thus, they ar not good candidates for IAD and other modalities should be considered.
Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL
J Urol. 2008 Jul 15. Epub ahead of print.
doi:10.1016/j.juro.2008.05.009
Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS
UroToday - the only urology website with original content scripted by world urology winder opinion leadership actively intermeshed in clinical practice.
To access the in vogue urology word releases from UroToday, go to:
www.urotoday.com
Copyright � 2008 - UroToday
More information
The patients were accrued between 1997 and 2003 and had a life expectancy of at least 12 months. A 24 week flow in of continuous LHRH agonist therapy preceded randomisation for those who had a PSA decrease to
Mean patient role age was 72 days and hateful PSA at entry was 383ng/ml. Patients had point T3 tumors (61%) and stage T4 tumors (29%). A come of 564 men completed the row period and 279 were randomized to IAD and 285 to CAD. PSA, alkaline phosphatase, proportion of T4 tumors, poorly differentiated tumors, metastatic disease, and skeletal hot spots among patients with M1 disease were significantly higher in the IAD group. Baseline testosterone was not important in the analysis.
A significant proportion of patients with the most fast-growing and advance CaP did not reply to androgenic hormone deprivation therapy. The investigators concluded that IAD appears feasible for patients with locally advanced, hormone sore CaP. A low limit of testosterone at baseline did non select for IAD or CAD. Patients with advanced CaP, with a high PSA, alkaline phosphatase and metastatic disease, with more than 5 skeletal hot spots, did not read adequate biochemical response to ADT. Thus, they ar not good candidates for IAD and other modalities should be considered.
Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL
J Urol. 2008 Jul 15. Epub ahead of print.
doi:10.1016/j.juro.2008.05.009
Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS
UroToday - the only urology website with original content scripted by world urology winder opinion leadership actively intermeshed in clinical practice.
To access the in vogue urology word releases from UroToday, go to:
www.urotoday.com
Copyright � 2008 - UroToday
More information
Monday, 11 August 2008
Colm Wilkinson
Artist: Colm Wilkinson
Genre(s):
Soundtrack
Discography:
Les Miserables (1987 Original Broadway Cast) cd2
Year: 1990
Tracks: 16
Les Miserables (1987 Original Broadway Cast) cd1
Year: 1990
Tracks: 18
DJ Nelson
Wednesday, 2 July 2008
Amy Winehouse - Winehouse Lunges At Fan
Troubled singer AMY WINEHOUSE stunned followers at the U.K.'s Glastonbury festival after seemingly attacking a fan.
The 24-year-old was singing her hit track Rehab to 75,000 fans on the Pyramid Stage on Saturday (28Jun08) when she jumped from the stage and into the security pit.
The star - who has been receiving medical attention for the lung disease emphysema - then appeared to lash out at a fan, striking the unnamed devotee with her fist.
But a spokesman for Winehouse insists she was provoked, adding, "The 'lashing out' was when someone tried to grab her hair and she reacted."
Winehouse also hit back at fans who booed her as she paid tribute to her incarcerated husband Blake Fielder-Civil.
She said, "Boo me one more time and I'll find you and your phone and call your mum and tell her you ain't got no manners."
See Also
Monday, 30 June 2008
Hilary Duff Plays It ‘Cool’
Photo: Getty Images
But Is She Too Cool for School?: Hilary Duff has joined Winona Ryder, Sean Astin, and Chevy Chase in Mark and Michael Polish's Stay Cool, a "knowing-your-age" comedy about a successful author who meets up with his unrequited high-school crush when he comes back to deliver a high-school graduation speech. Duff will play a "sexy high school senior who flirts with the visiting author and invites him to prom." She can currently be seen in John Cusack's War, Inc., playing who-cares-it's-terrible-don't-see-it. [HR]
Showtime Falls for Clooney: George Clooney has set up The Fall of Bob at Showtime, a half-hour comedy about a man whose life flashes before his eyes as he jumps off a building. We can already tell that this series' finale is going to have a huge impact. [Variety]
Millar Is Wanted for Sequel: Another score for primary-source Internet news! Mark Millar has posted on his own message board that he's already in talks to develop Wanted 2 for Universal because "everyone knows this is going to make a LOT of dough." [Comingsoon]
White Also Rocking Sequel: Another score for primary-source live-human news! Mike White tells a panel at the Los Angeles Film Festival that he just turned in a script for School of Rock 2, and that he can't go into it, but it made him cry. We would cry tears of joy at a sequel to Chuck & Buck. Oodly oodly oodly oodly oodly oodly fun fun fun! [Defamer]
Jonaspocalypse Now Redux: Just like the T-1000 in Terminator 2, shoot The Jonas Brothers as much as you want, but they'll always come back and they won't stop until you're good and dead. Even after its lackluster ratings by HSM2 standards, Disney Channel wasted no time in announcing a Camp Rock sequel, thus postponing Jonas Judgment Day to at least fall '09. [HR]
Cowell Is Going to Hollywood: Simon Cowell's Paul Potts project, One Chance, is moving ahead at Paramount now that The Bucket List's Justin Zackman is aboard to write the script. If you somehow aren't one of the 26 gazillion people who've seen his amazing story of becoming an opera singer via a spot on Britain's Got Talent, watch this YouTube video immediately. We must say, Paul Potts, you've come a long way from being a brutal Cambodian dictator. [HR]
But Is She Too Cool for School?: Hilary Duff has joined Winona Ryder, Sean Astin, and Chevy Chase in Mark and Michael Polish's Stay Cool, a "knowing-your-age" comedy about a successful author who meets up with his unrequited high-school crush when he comes back to deliver a high-school graduation speech. Duff will play a "sexy high school senior who flirts with the visiting author and invites him to prom." She can currently be seen in John Cusack's War, Inc., playing who-cares-it's-terrible-don't-see-it. [HR]
Showtime Falls for Clooney: George Clooney has set up The Fall of Bob at Showtime, a half-hour comedy about a man whose life flashes before his eyes as he jumps off a building. We can already tell that this series' finale is going to have a huge impact. [Variety]
Millar Is Wanted for Sequel: Another score for primary-source Internet news! Mark Millar has posted on his own message board that he's already in talks to develop Wanted 2 for Universal because "everyone knows this is going to make a LOT of dough." [Comingsoon]
White Also Rocking Sequel: Another score for primary-source live-human news! Mike White tells a panel at the Los Angeles Film Festival that he just turned in a script for School of Rock 2, and that he can't go into it, but it made him cry. We would cry tears of joy at a sequel to Chuck & Buck. Oodly oodly oodly oodly oodly oodly fun fun fun! [Defamer]
Jonaspocalypse Now Redux: Just like the T-1000 in Terminator 2, shoot The Jonas Brothers as much as you want, but they'll always come back and they won't stop until you're good and dead. Even after its lackluster ratings by HSM2 standards, Disney Channel wasted no time in announcing a Camp Rock sequel, thus postponing Jonas Judgment Day to at least fall '09. [HR]
Cowell Is Going to Hollywood: Simon Cowell's Paul Potts project, One Chance, is moving ahead at Paramount now that The Bucket List's Justin Zackman is aboard to write the script. If you somehow aren't one of the 26 gazillion people who've seen his amazing story of becoming an opera singer via a spot on Britain's Got Talent, watch this YouTube video immediately. We must say, Paul Potts, you've come a long way from being a brutal Cambodian dictator. [HR]
Cross Canadian Ragweed
Artist: Cross Canadian Ragweed
Genre(s):
Country
Rock
Discography:
Back to Tulsa: Live and Loud at Cain's Ballroom
Year: 2006
Tracks: 24
Garage
Year: 2005
Tracks: 14
Soul Gravy
Year: 2004
Tracks: 12
Highway 377
Year: 2004
Tracks: 12
Cross Canadian Ragweed conventional itself as a persistent touring band throughout the Texas/Oklahoma area and and so broadened its hit, nationally releasing several albums of rebel-rousing alt-country. Formed in 1994 in Stillwater, OK, the set took its name from those of its members: frontman and lead guitarist Cody Canada, drummer Randy Ragsdale, cycle guitarist Grady Cross, and bassist Jeremy Plato. Though the set toured heavily from its origin, establishing a particularly strong fan base in Texas, it didn't acquittance its first base album until 2001 when Underground Sounds released Highway 377. Two more releases for the label followed, Live and Loud at the Wormy Dog (2001) and Carney (2002), earlier the dance band affected to Smith Music Group for Live and Loud at Billy Bob's Texas (2002). In 2004 the group signed to Universal South and released Soul Gravy, followed by Garage in October of 2005.
Naomi Campbell Pleads Guilty to Assault Charges
Subscribe to:
Posts (Atom)